why choose us

First received: June 02, 2023

Clinical Trial: Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: NK Cell

Study Type: INTERVENTIONAL


Official Title: Xiangyang No.1 People's Hospital, Hubei University of Medicine

Brief Summary: This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma.The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine.The population was relapsed/refractory non-Hodgkin's B-cell lymphoma.The sample size was 33.The intervention was R-GemOx regimen combined with autologous NK cells.The dose of autologous NK cells was body surface area x (2-4) x 109 cells.The course of treatment was once every 14 days.The…

Read more